Follow
Birgit Wilding
Birgit Wilding
Unknown affiliation
Verified email at boehringer-ingelheim.com
Title
Cited by
Cited by
Year
Demonstrating in-cell target engagement using a pirin protein degradation probe (CCT367766)
NEA Chessum, SY Sharp, JJ Caldwell, AE Pasqua, B Wilding, ...
Journal of medicinal chemistry 61 (3), 918-933, 2018
902018
Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen
Journal of Medicinal Chemistry 60 (1), 180-201, 2017
502017
Nitrile reductase from Geobacillus kaustophilus: a potential catalyst for a new nitrile biotransformation reaction
B Wilding, M Winkler, B Petschacher, R Kratzer, A Glieder, N Klempier
Advanced Synthesis & Catalysis 354 (11‐12), 2191-2198, 2012
382012
Targeting the Substrate Binding Site of E. coli Nitrile Reductase QueF by Modeling, Substrate and Enzyme Engineering
B Wilding, M Winkler, B Petschacher, R Kratzer, S Egger, G Steinkellner, ...
Chemistry–A European Journal 19 (22), 7007-7012, 2013
312013
Newest Developments in the Preparation of Thieno[2,3-d]pyrimidines
B Wilding, N Klempier
Organic Preparations and Procedures International 49 (3), 183-215, 2017
282017
An investigation of nitrile transforming enzymes in the chemo-enzymatic synthesis of the taxol sidechain
B Wilding, AB Veselá, JJB Perry, GW Black, M Zhang, L Martínková, ...
Organic & biomolecular chemistry 13 (28), 7803-7812, 2015
212015
Privileged structures and polypharmacology within and between protein families
J Meyers, NEA Chessum, S Ali, NY Mok, B Wilding, AE Pasqua, ...
ACS Medicinal Chemistry Letters 9 (12), 1199-1204, 2018
192018
Chemoenzymatic one-pot reaction from carboxylic acid to nitrile via oxime
M Horvat, V Weilch, R Rädisch, S Hecko, A Schiefer, F Rudroff, B Wilding, ...
Catalysis Science & Technology 12 (1), 62-66, 2022
162022
A practical synthesis of 5-functionalized thieno [2, 3-d] pyrimidines
B Wilding, S Faschauner, N Klempier
Tetrahedron letters 56 (30), 4486-4489, 2015
162015
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
B Wilding, D Scharn, D Böse, A Baum, V Santoro, P Chetta, R Schnitzer, ...
Nature Cancer 3 (7), 821-836, 2022
102022
Kinetic analysis and probing with substrate analogues of the reaction pathway of the nitrile reductase QueF from Escherichia coli
J Jung, T Czabany, B Wilding, N Klempier, B Nidetzky
Journal of Biological Chemistry 291 (49), 25411-25426, 2016
82016
A convenient synthetic route to substituted pyrrolo [2, 3-b] pyridines via a novel ethylene-bridged compound
B Wilding, C Vidovic, N Klempier
Tetrahedron letters 56 (47), 6606-6609, 2015
72015
The Nitrile‐Forming Enzyme 7‐Cyano‐7‐Deazaguanine Synthase from Geobacillus kaustophilus: A Reverse Nitrilase?
M Winkler, K Dokulil, H Weber, T Pavkov‐Keller, B Wilding
ChemBioChem 16 (16), 2373-2378, 2015
72015
Targeting protein synthesis, folding, and degradation pathways in cancer
AE Pasqua, B Wilding, MD Cheeseman, K Jones
Elsevier, 2017
62017
Investigating the phosphinic acid tripeptide mimetic DG013A as a tool compound inhibitor of the M1-aminopeptidase ERAP1
B Wilding, AE Pasqua, NEA Chessum, OA Pierrat, T Hahner, K Tomlin, ...
Bioorganic & Medicinal Chemistry Letters 42, 128050, 2021
32021
Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity
K Jones, M Cheeseman, N Chessum, E Pasqua, L Evans, M Tucker, ...
US Patent 10,647,678, 2020
32020
HSF1 pathway inhibitor clinical candidate (CCT361814/NXP800) developed from a phenotypic screen as a potential treatment for refractory ovarian cancer and other malignancies
AE Pasqua, SY Sharp, NEA Chessum, A Hayes, L Pellegrino, MJ Tucker, ...
Journal of Medicinal Chemistry 66 (8), 5907-5936, 2023
22023
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
J Broeker, J Abbott, CUI Jianwen, SW Fesik, J Fuchs, A Gollner, L Herdeis, ...
US Patent App. 18/060,053, 2023
12023
Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need
RA Neumüller, B Wilding, D Scharn, D Böse, V Santoro, D Gerlach, ...
Cancer Research 81 (13_Supplement), 1472-1472, 2021
12021
Unconventional Enzymatic Reductions: Nitriles and Carboxylates as Substrates
M Winkler, K Napora-Wijata, B Wilding, N Klempier
16th European Congress on Biotechnology, 2014
12014
The system can't perform the operation now. Try again later.
Articles 1–20